Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
News
OCCIDENT is part of the Helmholtz Enterprise Jury
OCCIDENT as a science investor is proud to work with the German Helmholtz Association to help turn innovative science into great start-ups.
OCCIDENT celebrates 10 years of supporting young talent through CO-OPERAID
OCCIDENT's long-term partnership with CO-OPERAID empowers youth through education, transforming lives and communities in developing nations.
OCCIDENT welcomes the Venture Leaders Cleantech 2024
For the fourth year in a row, we were able to see 10 exciting start-up pitches and spend an inspiring networking evening.
ReCatalyst is celebrating major achievements
Our portfolio company ReCatalyst reaches significant product milestones and signs a memorandum of understanding with a Membrane Electrode Assembly producer.
Initial Investment in Lymphatica
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients suffering from lymphedema.
World Sepsis Day on September 13, 2024
On the occasion of World Sepsis Day on September 13, we want to raise awareness about sepsis, a life-threatening condition that impacts millions globally each year.
The OCCIDENT Team explores Milan
This year's team offsite event in Milan gave us the opportunity to enjoy the Italian way of life at its best.
Celebrating 10 years of Cédric at OCCIDENT
We are proud that Cédric has accompanied us over the last ten years and would like to take this opportunity to say THANK YOU to him!